目前已分离出T淋巴细胞识别的小鼠和人的肿瘤排斥抗原的第一个编码基因.其它此类基因可望在不远的将来鉴定出来.本文将简要地概述作者在这方面的研究进展,并探讨在此基础上新的肿瘤特异免疫疗法产生的可能性.虽然作者的研究限于细胞毒T淋巴细胞(CTL)的识别的抗原,但这并不意味着由CTL介导的细胞毒作用是肿瘤排斥仅有的或最有效的机制.事实上,作者已经遇到了几例在几乎缺乏CTL情况下,非常强烈的肿瘤排斥现象.但CTL克隆已充分证明是有效的和可靠的用遗传学方法分析研究肿瘤排斥抗原的工 The first coding gene for tumor rejection antigens recognized by T lymphocytes has now been isolated, and other such genes are expected to be identified in the near future.This article gives a brief overview of the authors’ research progress in this area , And explores the possibility of a new tumor-specific immunotherapy based on this.Although the authors’ study is limited to antigens recognized by cytotoxic T lymphocytes (CTLs), this does not imply that CTL-mediated cytotoxicity Is the only or most effective mechanism for tumor rejection.In fact, the authors have encountered several cases of very strong tumor rejection in the absence of CTL, but CTL clones have been well documented to be effective and reliable in genetics Methods Analyze the work of tumor rejection antigens